UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Portfolio Pulse from
Crinetics Pharmaceuticals is set to present its advancements in neuroendocrine tumor treatments at the NANETS Annual Meeting. The company will debut its novel nonpeptide drug conjugate platform, highlighting the preclinical profile of its lead candidate CRN09682, which targets SST2-expressing tumors and is expected to submit an IND by early 2025.
November 14, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals will showcase its pipeline advancements at the NANETS Annual Meeting, focusing on its lead candidate CRN09682 for neuroendocrine tumors. The IND submission is planned for early 2025.
The presentation of Crinetics' novel drug platform and the progress of CRN09682 at a major conference is likely to generate positive attention and investor interest. The planned IND submission indicates a clear development timeline, which is a positive signal for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90